OBJECTIVES: Inherited genetic variability contributes to susceptibility to cervical cancer. We investigated the association of single nucleotide polymorphisms (SNPs) in the human epidermal growth factor receptor (ERBB) family with cervical cancer. METHODS: We used the transmission disequilibrium test (TDT) to look for excessive transmission of tag single nucleotide polymorphisms (tSNPs) in ERBB family members EGFR, ERBB2, ERBB3, and ERBB4 in a large sample of women with invasive and in situ cervical cancer and their biological parents (628 trios). The study used a discovery set of trios (244) analyzed by Illumina GoldenGate in which SNPs reaching a P<.05 were re-tested by TaqMan in the combined set of 628. We also explored collaborative effects of different ERBB alleles. RESULTS: Based on single SNP TDT tests we identified 16 significant SNPs in the discover stage and six of 14 SNPs that could be assayed by TaqMan were significantly overtransmitted in women with cervical cancer in the combined replication set. Four SNPs were located in intron 1 of EGFR and two SNPs in intron 24 of ERBB4. The EGFR variants are located near multiple enhancers, silencers, and the previously identified functional common polymorphisms in intron 1. CONCLUSIONS: Our data provide evidence for the involvement of intron 1 EGFR variants and intron 24 ERBB4 variants in modulating risk for the development of in situ and invasive cervical cancer. These variants should be examined in additional populations and functional studies would be needed to confirm this hypothesis.
OBJECTIVES: Inherited genetic variability contributes to susceptibility to cervical cancer. We investigated the association of single nucleotide polymorphisms (SNPs) in the humanepidermal growth factor receptor (ERBB) family with cervical cancer. METHODS: We used the transmission disequilibrium test (TDT) to look for excessive transmission of tag single nucleotide polymorphisms (tSNPs) in ERBB family members EGFR, ERBB2, ERBB3, and ERBB4 in a large sample of women with invasive and in situ cervical cancer and their biological parents (628 trios). The study used a discovery set of trios (244) analyzed by Illumina GoldenGate in which SNPs reaching a P<.05 were re-tested by TaqMan in the combined set of 628. We also explored collaborative effects of different ERBB alleles. RESULTS: Based on single SNP TDT tests we identified 16 significant SNPs in the discover stage and six of 14 SNPs that could be assayed by TaqMan were significantly overtransmitted in women with cervical cancer in the combined replication set. Four SNPs were located in intron 1 of EGFR and two SNPs in intron 24 of ERBB4. The EGFR variants are located near multiple enhancers, silencers, and the previously identified functional common polymorphisms in intron 1. CONCLUSIONS: Our data provide evidence for the involvement of intron 1 EGFR variants and intron 24 ERBB4 variants in modulating risk for the development of in situ and invasive cervical cancer. These variants should be examined in additional populations and functional studies would be needed to confirm this hypothesis.
Authors: H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: Weiping Zhang; Joel L Weissfeld; Marjorie Romkes; Stephanie R Land; Jennifer R Grandis; Jill M Siegfried Journal: Mol Carcinog Date: 2007-05 Impact factor: 4.784
Authors: Wanqing Liu; Federico Innocenti; Michael H Wu; Apurva A Desai; M Eileen Dolan; Edwin H Cook; Mark J Ratain Journal: Cancer Res Date: 2005-01-01 Impact factor: 12.701
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: T Soonthornthum; H Arias-Pulido; N Joste; L Lomo; C Muller; T Rutledge; C Verschraegen Journal: Ann Oncol Date: 2011-02-16 Impact factor: 32.976
Authors: Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister Journal: Int J Cancer Date: 2019-01-04 Impact factor: 7.396
Authors: Alireza Torabi; Javier Ordonez; Brenda Bin Su; Laura Palmer; Chunxiang Mao; Katherine E Lara; Lewis P Rubin; Chun Xu Journal: Med Sci (Basel) Date: 2016-08-03
Authors: P-Y Hsu; H-K Hsu; T-H Hsiao; Z Ye; E Wang; A L Profit; I Jatoi; Y Chen; N B Kirma; V X Jin; Z D Sharp; T H-M Huang Journal: Oncogene Date: 2015-08-24 Impact factor: 9.867